A5049198126- Sarcoma Diagnosis and Treatment
- Head and Neck Cancer Studies
- Lymphoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Pancreatic and Hepatic Oncology Research
- Virus-based gene therapy research
- Lung Cancer Treatments and Mutations
- Herpesvirus Infections and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Thyroid Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Pancreatitis Pathology and Treatment
- Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Liver Disease Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Liver physiology and pathology
- Hedgehog Signaling Pathway Studies
- Gallbladder and Bile Duct Disorders
- Cardiac tumors and thrombi
- Renal cell carcinoma treatment
- Lung Cancer Research Studies
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Hypoxia, and Metabolism
Kokura Memorial Hospital
2023-2025
National Center for Global Health and Medicine
2025
Japanese Foundation For Cancer Research
2015-2024
The Cancer Institute Hospital
2013-2024
Tokyo Medical and Dental University
2024
Tohoku University
2023-2024
Memorial Sloan Kettering Cancer Center
2024
University of Tokyo Hospital
2024
Niigata City General Hospital
2019-2020
Kyoto University
1971-2019
Lenvatinib has been approved by regulatory agencies in Japan, the United States, and European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic (ATC), subtype associated with highest lethality. Effective therapy ATC an unmet need.This phase 2, single-arm, open-label study patients including ATC, RR-DTC, medullary was conducted from 3 September 2012 to 9 July 2015. Patients...
To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated cancer (RR-DTC), medullary (MTC) or anaplastic (ATC) received once-daily 24 mg. The primary end point was safety.All experienced ≥1 adverse event (AE); only one patient an AE leading to discontinuation. most common any-grade AEs were hypertension, decreased appetite, palmar-plantar erythrodysesthesia, fatigue proteinuria....
Glioblastoma multiforme (GBM) remains an untreatable human brain malignancy. Despite promising preclinical studies using oncolytic herpes simplex virus (oHSV) vectors, efficacy in patients has been limited by inefficient replication tumor cells. This disappointing outcome can be attributed part to attenuating mutations engineered into these viruses prevent normal Alternatively, retargeting of fully replication-competent HSV tumor-associated receptors the potential achieve specificity without...
CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also indicated that high-level expression of FOXP3 (FOXP3high) is sufficient confer suppressive activity normal non-Treg. Here, we showed for the first time vascular endothelial growth factor receptor 2 (VEGFR2) selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist tissues including PBMC and malignant effusion-derived...
Background: A standard chemotherapy for recurrent/metastatic salivary gland cancers has not been established. Combination of carboplatin and paclitaxel should be evaluated as a treatment option.Methods: This study retrospectively reviewed cancer patients who received combination paclitaxel. The differences in objective responses the prognoses according to different pathological diagnoses were evaluated.Results: total 38 enrolled study; them, 18 had duct carcinomas (SDCs), nine adenoid cystic...
Abstract Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 through interruption of the MDM2‐p53 interaction. This phase I, dose‐escalating study assessed safety, tolerability, efficacy, and pharmacokinetics milademetan 18 Japanese patients solid tumors who relapsed after or were refractory standard therapy. Patients aged ≥ 20 years received oral once daily (60 mg, n = 3; 90 11; 120 4)...
Abstract In our present study, we examined whether nuclear localization of Y-box binding protein-1 (YB-1) is associated with the expression epidermal growth factor receptors (EGFR), hormone receptors, and other molecules affecting breast cancer prognosis. The YB-1, clinicopathologic findings, molecular markers [EGFR, HER2, estrogen receptor (ER)α, ERβ, progesterone receptor, chemokine (C-X-C motif) 4 (CXCR4), phosphorylated Akt, major vault protein/lung resistance protein] were...
Survivin, an apoptotic inhibitor, is overexpressed in the majority of human tumor types and represents a novel target for anticancer therapy. Taxanes induce mitotic cell-cycle block through inhibition microtubule depolymerization, with subsequent elevated expression/stabilization survivin. We investigated administration survivin suppressant YM155 monobromide (YM155), combination docetaxel, non-small-cell lung cancer (NSCLC) xenograft model. Animals received 7-day continuous infusion YM155, 2...
Gallbladder cancer ( GBC ) is a particularly deadly type of with 5‐year survival rate only 10%. New effective therapeutic strategies are greatly needed. Recently, we have shown that Hedgehog (Hh) signaling reactivated in various types and potential target. However, little known about the biological significance Hh human . In this study, determined whether could be target The transcription factor Gli1 was detected nucleus cells but not normal gallbladder cells. expression levels Sonic (Shh)...
An inflammatory myofibroblastic tumor is a rare component of bone and soft-tissue sarcomas that has distinct pathological features as lymphoplasmacytic infiltrate. As the case for other non-small round cell sarcomas, surgical resection remains standard treatment strategy tumors, but recurrence possible. Concerning systemic therapy, available data conventional chemotherapy (such those doxorubicin-based regimens) are limited, reports anti-inflammatory treatments describe some degree symptom...